ArticleJournal of hematology & oncology2016

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.

Christian Lehmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.